View on market: Stay Cautious, be with quality business:

Asian stocks opened firmer Tuesday as investors weighed a pick-up in virus cases in the region against the pace of economic growth as economies reopen. U.S. futures rose. Benchmarks climbed in Japan, Australia and South Korea. Nasdaq 100 futures outperformed. Earlier, technology and communication services stocks led the benchmark S&P 500 lower, while energy shares rose.

The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, rose 1.12% to 15,113 as of 8:02 a.m.

Oil held an advance to a two-year high as rising optimism around a demand recovery in regions such as the U.S. offset Covid-19 flare-ups in parts of Asia.

Key Data/ Action, Result,IPO and Board meeting to watch

Major economic Data:

  • INR: Deposit Growth YoY MAY on 21st May, 2021
  • INR: Bank Loan Growth YoY MAY on 21st May, 2021
  • USD: Building Permits (Apr) on 18th May, 2021
  • USD: Crude oil Inventories on 19th May,2021

Nifty Results: TATA Motors

International Markets:

U.S & Europe

Particulars    17th May. Chg Chg(%)
Nasdaq 13,379.05 -50.93 -0.38
Dow 34327.79  -54.34 -54.34
FTSE 7,032.85 -10.76 -0.15
CAC 6,367.35 -17.79 -0.28
DAX 15,396.62 -20.02 -0.13
Dow Fut.* 34,355.00 99 0.29

Asian markets:

Particulars    18th May. Chg Chg(%)
SGX Nifty 15,113.50 167.5 1.12
Nikkei 28,399.34 574.51 2.06
Straits Times 3,123.11 43.42 1.41
Hang Seng 28,574.28 380.19 1.35
Shanghai 3,521.16 3.54 0.1

ADR Watch:

Particulars       17th May. Chg Chg(%)
Dr Reddy 72.0 0.00 0.00
HDFC Bank 71.65 1.57 2.24
ICICI Bank 17.05 0.51 3.08
Infosys 18.17 0.01 0.06
Tata Motor 21.90 0.66 3.11
Wipro 7.31 -0.08 -1.08

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR 73.21 -0.10
Brent 69.56 0.14
Gold 1870.40 0.15
Silver 28.633 1.27


Particulars   17th May. 14th May.
FIIs -2255.84 -2607.85
DIIs 1948.48 613.26


Non-Nifty Results:

Aarti Industries, Abbott India, Astral, Brigade Enterprises, Canara Bank, Chalet Hotels, GlaxoSmithKline Pharmaceuticals, Gujarat Alkalies & Chemicals, Jyothy Labs, Manappuram Finance, Minda Corp, PI Industries, Torrent Pharmaceuticals.

Bharti Airtel Q4FY21 (Consolidated, QoQ) Revenues down 2.9% at Rs 25,747.3 crore Vs Rs 26,517.8 crore (BBG Estimate: Rs 26,165 crore) Net profit down 11.1% at Rs 759.2 crore Vs Rs 853.6 crore (BBG Estimate: Rs 958.8 crore) Ebitda up 2.3% at Rs Rs 12,331.9 crore Vs Rs 12,053 crore (BBG Estimate: Rs 12,626 crore) Ebitda margin at 47.9% Vs 45.5% (BBG Estimate: 48.3%) Overall customer base stands at 471 million across 16 countries Total Capex spend for the quarter of Rs 6,846 crore

Gland Pharma Q4FY21 (Consolidated, QoQ) Revenue up 3% at Rs 887.70 crore Vs Rs 859.40 crore Net profit up 28% at Rs 260.40 crore Vs Rs 204.10 crore Ebitda up 24% at Rs 327.60 crore Vs Rs 264.10 crore Ebitda margin at 36.9% Vs 30.7%.

Brokerage Radar:

CLSA on Bharti Airtel: Maintain Buy at the Target Price of Rs.730.Gained more than expected 4G Data Subscriberjio on most metricss. ARPU, Net of IUC, Although was Down 0.8% Q-o-Q/up 7.4% Y-o-Y.4G Penetration of 56% of its own subscribers Assures growth.

CITI on Bharti Airtel: Maintain Buy at the Target price of Rs.685Q4 overall in Line;India Mobile EBITDA A shade Below.Adj Pre-tax profit of Rs.1580 Cr ahead of our Estimate. Profit Boosted by Rs.440 cr of Net Exceptional Gains.

UBS on Bharti Airtel: Maintain Buy at the Target Price of Rs.655.A Healthy set of results with co outperforming  jio on most metrics.Impact of COVID on Subscriber Adds & ARPUs key monitorable Going Ahead.

News Update:

Bharat Forge:

To purchase a 49% stake in its subsidiary, Kalyani Strategic Systems, for Rs 32.97 crore. Currently, the company holds a 51% stake in KSSL. After this acquisition, KSSL shall become a wholly-owned subsidiary of the company.

HCL Technologies:

Announced expansion of investment in the United Kingdom with the hiring of 1000 technology professionals to support its clients in the U.K. and around the world.

Zuari Agro Chemicals:

Company said its Goa fertiliser plant has been hit by the cyclonic storm Tauktae. It is assessing damages by the cyclone to the plant. There could be a potential delay in restarting ammonia, urea plants.

Kotak Mahindra Bank:

Acquired 1.3 crore equity shares, representing 46.7% of the issued and paid-up equity share capital of Kotak Mahindra Pension Fund Limited from Kotak Mahindra Asset Management Company Limited for Rs 12.71 crore. After this acquisition, the bank’s shareholding in KMPFL will increase from 4.3% to 51%. Also, KMPFL has now become a direct subsidiary of the bank.

Strides Pharma Sciences:

Promoter pledge reduced by 38%. Currently, the overall promoter group pledge stands at 25.98% of the promoter holding and 7.71% of the paid-up capital of the company as compared to 41.96% of the promoter holding and 12.45% of the paid-up capital as of May 7.

Hemisphere Properties India:

Board has allotted 10 crore Non-Cumulative Redeemable Preference Shares of Rs 10 each at par aggregating to Rs 100 crore on a private placement basis to the Promoter President of India.

Upcoming IPO:

Krsnaa Diagnostic seeks Sebi Approval for IPO

Source: Moneycontrol, Livemint,, Bloomberg, Investing, Business Standard

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit Disclosures Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting , or e-mailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person. Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company in the analyst’s area of coverage. Country Specific Disclosures India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking
or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.